SCHEMBL5832686

SCHEMBL5832686

BrCc1ccc(-c2nc3ccccc3o2)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.51
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 6/20 0.51
RAB9A P51151 5/20 0.51
HPGD P15428 5/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
TP53 P04637 3/20 0.51
HSD17B10 Q99714 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ATM Q13315 1/20 0.51
NFKB1 P19838 2/20 0.48
STAT1 P42224 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
HCRTR1 O43613 2/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11696502 0.84 NPC1 (0.50) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5832530 0.84 PTGS2 (0.52) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5832027 0.84 NPC1 (0.47) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5833047 0.81 HSPD1 (0.48) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5832760 0.81 NPC1 (0.71) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL11376453 0.81 NPC1 (0.47) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5831975 0.79 NPC1 (0.68) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL751887 0.78 NPC1 (0.53) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5832553 0.77 NPC1 (0.55) NPC1KDM4EALDH1A1RAB9AHPGD
SCHEMBL5832705 0.77 NPC1 (0.58) NPC1KDM4EALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885KDM4E 1754/4885ALDH1A1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.